Cross Reactive Epitope Group antibodies in sensitized kidneys transplant recipients was associated with early acute Antibody Mediated Rejection

Transplant Immunology

Volumn 20, Issue 3, 2009, Pages 113-117

  Nainani, Neha ^a,b   Singh, Neeraj ^a,b   Shanahan, Thomas ^b   Damodar, Amar ^a,b   Parimoo, Nakul ^a,b   Ummadi, Sudheer ^a,b   Qazi, Yasir ^d   Murray, Brian M ^a,b   Tornatore, Kathleen M ^a,c   Ciccirella, James C ^d   Blessios, George A ^a,b   Venuto, Rocco C ^a,b  

^a ERIE COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antibody Mediated Rejection; Cross Reactive Epitope Group (CREG); Renal transplant

Indexed keywords

ALEMTUZUMAB; COMPLEMENT COMPONENT C4; CROSS REACTING ANTIBODY; CYCLOSPORIN A; HLA ANTIGEN; MEPREDNISONE; MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE VASCULAR REJECTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; GRAFT RECIPIENT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; EPITOPES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 57549098996     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.10.009     Document Type: Article

References (42)

1. Andreoni K.A., Brayman K.L., Guidinger M.K., Sommers C.M., and Sung R.S. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 7 5 Pt 2 (2007) 1359-1375
2. Mauiyyedi S., Crespo M., Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., et al. Acute humoral rejection in kidney transplantation, II: morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 13 (2002) 779-787
3. Reisaeter A.V., Leivestad T., Vartdal F., Spurkland A., Fauchald P., Brekke I.B., et al. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: a single-center study of first cadaveric kidneys to nonsensitized recipients. Transplantation 66 (1998) 523-528
4. Opelz G. New immunosuppressants and HLA matching. Transplant Proc 33 (2001) 467-468
5. Morris P.J., Johnson R.J., Fuggle S.V., Belger M.A., and Briggs J.D. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 354 (1999) 1147-1152
6. Lois U.N., Williams J.A., Weiss E.A., Russell S.D., Baumgartner W.A., and Conte J.V. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 84 5 (Nov 2007) 1556-1562 discussion 1562--3
7. Lee K.W., Kim S.J., Lee D.S., Lee H.H., Joh J.W., Lee S.K., et al. Effect of panel-reactive antibody positivity on graft rejection before or after kidney transplantation. Transplant Proc 36 7 (Sep 2004) 2009-2010
8. Cardarelli F., Pascual M., Tolkoff-Rubin N., Delmonico F.L., Wong W., Schoenfeld D.A., et al. Prevalence and significance of anti-HLA and donor specific antibodies long-term after renal transplantation. Transpl Int 18 (2005) 532-540
9. Hourmant M., Cesbron-Gautier A., Terasaki P.I., Mizutani K., Moreau A., Meurette A., et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 16 9 (Sep 2005) 2804-2812
10. Takemoto S.K., Zeevi A., Feng S., Colvin R.B., Jordan S., Kobashigawa J., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 7 (Jul 2004) 1033-1041
11. Organ Procurement and Transplantation Network. Scientific registry of transplant recipients. (Accessed August 4, 2008, at http://www.optn.org/data/.)
12. Jordan S.C., and Pescovitz M.D. Presensitization: the problem and its management. Clin J Am Soc Nephrol 1 (2006) 421-432
13. Rodey G.E., and Fuller T.C. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 7 (1987) 229-267
14. Thompson J., and Thacker L. Effect of HLA-DR and class I cross-reactive group matching on first cardiac transplants: an analysis of access and outcome. Transplant Proc 30 (1998) 729
15. Duquesnoy R.J., Takemoto S., De Lange P., Doxiadis I.I., Schreuder G.M., Persijn G.G., et al. HLA matchmaker: a molecularly based algorithm for histocompatibility determination, III: effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival. Transplantation 75 (2003) 884-889
16. Takemoto S.K. HLA amino acid residue matching. Clin Transpl (1996) 397-425
17. Solez K., Colvin R.B., and Racusen L. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8 (2008) 753
18. Racusen L., Solez K., Colvin R.B., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 6 (2003) 708
19. Sanfilippo F., Vaughn W.K., Spees E.K., Heise E.R., and LeFor W.M. The effect of HLA-A, -B matching on cadaver renal allograft rejection comparing public and private specificities. Transplantation 38 (1984) 483-489
20. Takemoto S., Terasaki P.I., Gjertson D.W., and Cecka J.M. Equitable allocation of HLA compatible kidneys for local pools and minorities. N Engl J Med 331 (1994) 760-764
21. Starzl T.E., Eliasziw M., Gjertson D., Terasaki P.I., Fung J.J., Truco M., et al. HLA and cross-reactive antigen group matching for cadaver kidney allocation. Transplantation 64 (1997) 983-991
22. Piazza A., Canossi A., Buonomo O., Di Rocco M., Del Beato T., Torlone N., et al. HLA class I residue mismatch and renal graft outcome. Transpl Int 13 Suppl 1 (2000) S444-S448
23. McKenna R.M., Lee K.R., Gough J.C., Jeffery J.R., Grimm P.C., Rush D.N., et al. Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. Transplantation 66 (1998) 38-43
24. Lazda V.A., and Mozes M.F. An evaluation of HLA cross-reactive group matching on graft survival in deceased donor kidney recipients. Transplant Proc 37 2 (Mar 2005) 661-663
25. Laux G., and Opelz G. Immunological relevance of CREG matching in cadaver kidney transplantation. Transplantation 78 3 (Aug 15 2004) 442-446
26. Piazza A., Poggi E., Borelli L., Servetti S., Monaco P.I., Buonomo O., et al. Relevance of posttransplant HLA class I and class II antibodies on renal graft outcome. Transplant Proc 33 1-2 (2001) 478-480
27. C. Lorraine et al. Kidney transplant rejection diagnosis and treatment 3rd Edition. Revised and Expanded. Chapter 3 Mechanisms of Cell Mediated rejection pg 47.
28. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., and Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49 (1990) 85-91
29. Halloran P.F. The clinical importance of alloantibody-mediated rejection. Am J Transpl 3 (2003) 639-640
30. Halloran P.F., Schlaut J., Solez K., and Srinivasa N.S. The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I like antibody. Transplantation 53 (1992) 550-555
31. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15 (2004) 3256-3262
32. Jordan S.C., Vo A., Peng A., Toyoda M., and Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA sensitized patients. Am J Transplant 6 (2006) 459-466
33. Gloor J.M., DeGoey S.R., Pineda A.A., Moore S.B., Prierto M., Nyberg S.L., et al. Overcoming a positive crossmatch in living- donor kidney transplantation. Am J Transplant 3 (2003) 1017-1023
34. Montgomery R.A., Cooper M., Kraus E., Rabb H., Samaniego M., Simpkins C.E., et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clinic Transpl (2003) 199-213
35. Vo A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and Intravenous Immune Globulin for desensitization during Renal Transplantation. N Engl J Med 359 (2008) 242-251
36. Faguer S., Kamar N., Guilbeaud-Frugier C., Fort M., Modesto A., Mari A., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83 (2007) 1277-1280
37. Salama A.D., and Pusey C.D. Drug insight: Rituximab in renal disease in transplantation. Nat Clin Pract Nephrol 2 (2006) 221-230
38. Knetchtle S.J., Pirsch J.D., Fechner Jr. J.H., Becker B.N., Colvin R.B., Lebeck L.K., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3 (2003) 722
39. Ciancio G., Burke G.W., Gaynor J.J., Sageshima J., Herrada E., Tueros L., et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 78 (2004) 426
40. 4D positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction. Ann. Clin. Lab. Sci. 37 2 (2007)
41. Cai J., Terasaki P.I., Bloom D.D., Torrealba J.R., Friedl A., Sollinger H.W., et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 78 (2004) 919
42. Leventhal J.R., Gallon L., Buckingham M., Diaz R., Polyakov N., and Tambur A.R. A prospective nonrandomized trail of Alemtuzumab for desensitization of waiting list candidates with anti-HLA antibodies. Am J Transplant 6 (2006) 781